More recently, semaglutide in the STEP-1 trial produced mean weight losses of approximately 15% in individuals living with obesity [4] in a 68-week randomised trial of 1961 adults with overweight or obesity. The dual GIP/GLP-1 agonist tirzepatide in SURMOUNT-1 achieved reductions exceeding 20% in some participants [5], as demonstrated in a 72-week, phase 3 trial enrolling 2539 adults with obesity. These drugs have paved the way for the efficient invention of even more efficacious drugs in the future. Here, GIP is linked to obesity disorder.